Figure 4 from Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

Analysis of treatment-associated outcomes and effect of mutation status among patients in Caris CODEai clinico-genomic database. A and B, Kaplan–Meier analysis comparing posttreatment OS between patients with STK11-mutated (mut, blue lines) and STK11-wild type (wt, red lines) NSCLC treated with (A) carboplatin (no pembrolizumab) and (B) pembrolizumab (no carboplatin). C and D, Kaplan–Meier analysis comparing (C) posttreatment OS and (D) TOT between patients treated with pemetrexed (blue lines) and osimertinib (red lines) for EGFR-mut NSCLC. E and F, Kaplan–Meier analysis comparing posttreatment OS between patients with EGFR-mut (blue lines) and EGFR-wt (red lines) NSCLC treated with (E) osimertinib or (F) pemetrexed. G and H, Kaplan–Meier analysis comparing (G) posttreatment OS and (H) TOT between patients treated with fluorouracil (blue lines) and capecitabine (red lines) for colorectal cancer.